Related Experiment Video

Updated: May 13, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

717

Thrombotic thrombocytopenic purpura in pregnancy: a comprehensive review

Eman Alsulmi1

  • 1Department of Obstetrics and Gynecology, College of Medicine, 48023 Imam Abdulrahman Bin Faisal University , Al Khobar, Kingdom of Saudi Arabia.

Journal of Perinatal Medicine
|April 16, 2025
PubMed

Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening hemolytic disorder with severe implications during pregnancy, characterized by microangiopathic hemolytic anemia (MAHA), severe thrombocytopenia, and systemic microvascular thrombosis. The condition arises from a severe deficiency in the ADAMTS13 enzyme, whether congenital or acquired, leading to the accumulation of ultra-large von Willebrand factor (vWF) multimers and widespread platelet aggregation. Pregnancy itself exacerbates TTP due to physiological reductions in ADAMTS13 activity, necessitating a high degree of clinical vigilance. This review addresses the etiology, diagnostic challenges, clinical presentation, and management of TTP in pregnancy, focusing on clinical relevance and emphasizing the importance of prompt therapeutic plasma exchange (TPE) and interdisciplinary care to optimize maternal and fetal outcomes.

Keywords:
ADAMTS13 deficiencymicroangiopathic hemolytic anemiapregnancy-related thrombotic thrombocytopenic purpuratherapeutic plasma exchange

More Related Videos

Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus06:55

Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus

Published on: December 5, 2015

13.2K
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

9.6K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.9K